Electronic Resource
Staphylococcus Aureus peritonitis in Australian peritoneal dialysis patients: Predictors, treatment, and outcomes in 503 cases.
| العنوان: | Staphylococcus Aureus peritonitis in Australian peritoneal dialysis patients: Predictors, treatment, and outcomes in 503 cases. |
|---|---|
| المؤلفون: | Bannister K.M., Rosman J.B., Wiggins K.J., Johnson D.W., Govindarajulu S., Hawley C.M., Mcdonald S.P., Brown F.G. |
| بيانات النشر: | Multimed Inc. (66 Martin Street, Milton ONT L9T 2R2, Canada) Canada 2012-10-12 |
| نوع الوثيقة: | Electronic Resource |
| مستخلص: | Staphylococcus aureus peritonitis is a serious complication of peritoneal dialysis (PD). Since reports of the course and treatment of S. aureus peritonitis have generally been limited to small, single-center studies, the aim of the current investigation was to examine the frequency, predictors, treatment, and clinical outcomes of this condition in all 4675 patients receiving PD in Australia between 1 October 2003 and 31 December 2006. 3594 episodes of peritonitis occurred in 1984 patients and 503 (14%) episodes of S. aureus peritonitis occurred in 355 (8%) individuals. 273 (77%) patients experienced 1 episode of S. aureus peritonitis, 52 (15%) experienced 2 episodes, 19 (5%) experienced 3 episodes, and 11 (3%) experienced 4 or more episodes. The predominant antibiotics used as initial empiric therapy were vancomycin (61%) and cephazolin(31%). Once S. aureus was isolated and identified, the prescription of vancomycin did not appreciably change for methicillin-sensitive S. aureus (MSSA) peritonitis (59%) and increased for methicillin-resistant S. aureus (MRSA) peritonitis (84%). S. aureus peritonitis was associated with a higher rate of relapse than non-S. aureus peritonitis (20% vs 13%, p < 0.001) but comparable rates of hospitalization (67% vs 70%, p = 0.2), catheter removal (23% vs 21%, p = 0.4), hemodialysis transfer (18% vs 18%, p = 0.6), and death (2.2% vs 2.3%, p = 0.9). MRSA peritonitis was independently predictive of an increased risk of permanent hemodialysis transfer [odds ratio (OR) 2.11, 95% confidence interval (CI) 1.17 - 3.82] and tended to be associated with an increased risk of hospitalization (OR 2.00, 95% CI 0.96 - 4.19). The initial empiric antibiotic choice between vancomycin and cephazolin was not significantly associated with clinical outcomes, but serious adverse outcomes were more likely if vancomycin was not used for subsequent treatment of MRSA peritonitis. In conclusion, S. aureus peritonitis is a serious complication of PD, involves a smal |
| مصطلحات الفهرس: | major clinical study, male, methicillin resistant Staphylococcus aureus, outcome assessment, patient, prediction, prescription, priority journal, relapse, risk assessment, Staphylococcus aureus, amoxicillin/dt [Drug Therapy], amoxicillin/po [Oral Drug Administration], amoxicillin plus clavulanic acid/dt [Drug Therapy], amoxicillin plus clavulanic acid/po [Oral Drug Administration], amphotericin/dt [Drug Therapy], cefalexin/dt [Drug Therapy], cefalexin/po [Oral Drug Administration], cefalotin/dt [Drug Therapy], cefazolin/cb [Drug Combination], cefazolin/dt [Drug Therapy], cefoxitin/dt [Drug Therapy], ceftazidime/dt [Drug Therapy], ceftriaxone/dt [Drug Therapy], ciprofloxacin/dt [Drug Therapy], cloxacillin/dt [Drug Therapy], cloxacillin/po [Oral Drug Administration], dicloxacillin/dt [Drug Therapy], dicloxacillin/po [Oral Drug Administration], flucloxacillin/dt [Drug Therapy], flucloxacillin/po [Oral Drug Administration], fluconazole/dt [Drug Therapy], gentamicin/dt [Drug Therapy], nystatin/po [Oral Drug Administration], rifampicin/dt [Drug Therapy], streptokinase, teicoplanin/dt [Drug Therapy], urokinase, vancomycin/cb [Drug Combination], vancomycin/dt [Drug Therapy], peritoneal dialysis patient, catheter removal, adult, antibiotic therapy, article, Australia, bacterial peritonitis/co [Complication], bacterial peritonitis/dt [Drug Therapy], bacterial peritonitis/et [Etiology], bacterium identification, bacterium isolation, confidence interval, controlled study, death, drug choice, drug substitution, drug withdrawal, female, hemodialysis, hospitalization, human, Article |
| URL: | Click here for full text options LibKey Link |
| الاتاحة: | Open access content. Open access content Copyright 2012 Elsevier B.V., All rights reserved. |
| Other Numbers: | AUSHL oai:repository.monashhealth.org:1/31027 Peritoneal Dialysis International. 30 (3) (pp 311-319), 2010. Date of Publication: May/June 2010. 0896-8608 https://repository.monashhealth.org/monashhealthjspui/handle/1/31027 20190031 [http://www.ncbi.nlm.nih.gov/pubmed/?term=20190031] 359719609 (Govindarajulu, Hawley, Mcdonald, Brown, Rosman, Wiggins, Bannister, Johnson) Australia and New Zealand Dialysis and Transplant Registry, Adelaide, Australia (Govindarajulu, Hawley, Johnson) Department of Renal Medicine, University of Queensland, Princess Alexandra Hospital, Brisbane, Australia (Mcdonald) Department of Nephrology and Transplantation Services, University of Adelaide at the Queen Elizabeth Hospital, Adelaide, Australia (Brown) Department of Nephrology, Monash Medical Centre, Clayton, VIC, Australia (Rosman) Renal Department, Middlemore Hospital, Otahuhu, Auckland, New Zealand (Wiggins) Department of Medicine, University of Melbourne, St Vincent's Hospital, Fitzroy, VIC, Australia (Bannister) Department of Nephrology, Princess Alexandra Hospital, Level 2, ARTS Building, Ipswich Road, Woolloongabba, Brisbane Qld 4102, Australia Johnson D.W.; david_johnson@health.qld.gov.au 1305139038 |
| المصدر المساهم: | MONASH HEALTH LIBRS From OAIster®, provided by the OCLC Cooperative. |
| رقم الانضمام: | edsoai.on1305139038 |
| قاعدة البيانات: | OAIster |
| الوصف غير متاح. |